The retatrutide vs tirzepatide question comes down to one structural difference: how many hormone receptors each molecule activates. Tirzepatide is a dual agonist that hits two receptors and is already FDA-approved. Retatrutide is a triple agonist that adds a third, and as of 2026 it is still investigational. Both are peptide-based metabolic drugs, and the gap between them is really a gap in regulatory maturity, not just raw numbers.
The Compound Universe Take: Tirzepatide (Mounjaro, Zepbound) is an FDA-approved GIP and GLP-1 dual agonist with phase 3 data showing up to 22.5% mean weight loss. Retatrutide is an investigational GIP, GLP-1, and glucagon triple agonist that produced 24.2% mean weight loss in a single phase 2 trial, but it is not approved and lacks completed phase 3 results. Tirzepatide is the proven option today; retatrutide is the higher-ceiling candidate still being tested.
New here? Start with the tirzepatide research summary for the approved compound, then use this page to weigh it against retatrutide.
What retatrutide and tirzepatide actually are
Both compounds are incretin-based peptides that mimic gut hormones controlling appetite, insulin, and blood sugar. The difference is receptor count.
Tirzepatide combines GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonism in one molecule [2]. Retatrutide keeps both of those and adds a glucagon receptor agonist, which is thought to raise energy expenditure on top of suppressing appetite [1].
That third receptor is the whole thesis behind retatrutide. Whether it delivers a durable advantage over the dual approach is exactly what the ongoing phase 3 program is built to answer.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Drug class | Triple agonist (GIP / GLP-1 / glucagon) | Dual agonist (GIP / GLP-1) |
| Mechanism | Appetite suppression plus glucagon-driven energy expenditure | Appetite suppression and improved insulin response |
| Best studied for | Obesity, type 2 diabetes, fatty liver (phase 2) | Obesity, type 2 diabetes, sleep apnea (phase 3) |
| Evidence tier | Human (phase 2) | Human (phase 3) + Regulatory |
| Peak weight loss reported | 24.2% at 48 weeks (12 mg) | 22.5% at 72 weeks (15 mg) |
| US legal status | Investigational, not approved | FDA-approved (Mounjaro, Zepbound) |
Retatrutide: the triple agonist with the higher ceiling
Retatrutide is the more aggressive molecule on paper. By adding glucagon receptor activity to the GIP and GLP-1 pair, it aims to burn more energy while also curbing intake.
In a phase 2 obesity trial, retatrutide at 12 mg produced a mean weight reduction of 24.2% after 48 weeks, versus 2.1% for placebo (Human, phase 2) [1]. That trial randomized 338 adults and remains the headline efficacy signal for the compound.
Retatrutide has also been studied beyond weight. A separate phase 2a trial reported reductions in liver fat in people with metabolic dysfunction-associated steatotic liver disease (Human, phase 2a) [4]. The glucagon component is a plausible reason it shows a strong liver signal.
The honest limit is stage. A 48-week phase 2 result is promising, not confirmatory, and the pivotal phase 3 TRIUMPH program has not reported full outcomes. Retatrutide is investigational and not FDA-approved (Regulatory). Any product sold as retatrutide outside a trial is unapproved and often labeled research-use-only.
Tirzepatide: the approved dual agonist
Tirzepatide is the compound with the deeper, regulated evidence base. It reached the market first and carries multiple approvals.
In the phase 3 SURMOUNT-1 trial, tirzepatide produced mean weight loss of 16.0%, 21.4%, and 22.5% across its 5 mg, 10 mg, and 15 mg doses over 72 weeks, versus 2.4% for placebo (Human, phase 3) [2]. That trial enrolled 2,539 adults with obesity or overweight, a far larger and longer dataset than retatrutide’s phase 2.
Tirzepatide also has head-to-head data against semaglutide. In SURMOUNT-5, tirzepatide reduced body weight by 20.2% at 72 weeks compared with 13.7% for semaglutide (Human, phase 3b) [3]. That is the strongest comparative evidence any drug in this class currently holds.
The FDA approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023 (Regulatory). It is a prescription drug, not a research compound. That regulatory status is the clearest dividing line in the retatrutide vs tirzepatide comparison.
| Compound | Primary mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Retatrutide | Triple GIP / GLP-1 / glucagon agonism | Human phase 2; phase 3 ongoing | Investigational, not approved |
| Tirzepatide | Dual GIP / GLP-1 agonism | Human phase 3; head-to-head data | FDA-approved (Mounjaro, Zepbound) |
| Semaglutide | Single GLP-1 agonism | Human phase 3; long track record | FDA-approved (Ozempic, Wegovy) |
Read this before comparing numbers: Retatrutide’s 24.2% and tirzepatide’s 22.5% come from different trials with different lengths and populations, so the figures are not a direct head-to-head. This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Retatrutide is not FDA-approved and legal status varies by jurisdiction.
Key takeaways
- Tirzepatide is a dual GIP and GLP-1 agonist, FDA-approved for obesity and type 2 diabetes, with phase 3 data reaching 22.5% mean weight loss [2].
- Retatrutide is a triple agonist that adds glucagon receptor activity and hit 24.2% mean weight loss in a single phase 2 obesity trial [1].
- The retatrutide figure came from a 48-week phase 2 study, while tirzepatide’s came from a larger 72-week phase 3 trial, so the numbers are not directly comparable.
- Tirzepatide beat semaglutide head-to-head in SURMOUNT-5, at 20.2% versus 13.7% weight loss over 72 weeks [3].
- Retatrutide remains investigational, so tirzepatide is the only one of the two available as an approved prescription today.
Frequently asked questions
Is retatrutide better than tirzepatide?
Retatrutide showed a higher peak weight loss (24.2%) in phase 2 than tirzepatide did in phase 3 (22.5%), but those numbers come from separate trials. Until phase 3 head-to-head data exist, “better” is not established.
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates two receptors (GIP and GLP-1), while retatrutide activates three by adding glucagon. That extra receptor is meant to increase energy expenditure alongside appetite suppression.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug still in phase 3 testing as of 2026. Tirzepatide is FDA-approved as Mounjaro and Zepbound.
Is tirzepatide the same as Mounjaro and Zepbound?
Yes. Mounjaro and Zepbound both contain tirzepatide; the brand name reflects the approved indication (diabetes versus weight management), not a different molecule.
How do these compare with semaglutide?
Semaglutide is a single GLP-1 agonist. In the SURMOUNT-5 trial, tirzepatide produced greater weight loss than semaglutide, and retatrutide’s triple mechanism targets an even higher ceiling in earlier-stage research.
Can you buy retatrutide legally?
Retatrutide is not an approved medicine, so it is not sold as a prescription drug. Products marketed as retatrutide are typically unapproved and labeled for research use only, and legal status varies by jurisdiction.
The retatrutide vs tirzepatide comparison sits inside the fast-moving incretin field, where GLP-1 receptor agonism underpins semaglutide (Ozempic, Wegovy), the dual GIP and GLP-1 mechanism defines tirzepatide (Mounjaro, Zepbound), and the triple GIP, GLP-1, and glucagon design of retatrutide from Eli Lilly’s phase 3 TRIUMPH program pushes toward higher weight loss and stronger liver-fat effects; Compound Universe tracks each of these compounds against the primary trial literature so the framing reflects evidence maturity and regulatory status rather than marketing.
Choosing between these two is less about a single percentage and more about proof. Tirzepatide is the approved, phase-3-backed dual agonist; retatrutide is the investigational triple agonist with a higher ceiling but a thinner evidence base. For anyone weighing retatrutide vs tirzepatide in 2026, that difference in regulatory status is the fact that separates a prescription drug from a research-stage candidate.
Compare next: retatrutide research summary | how these stack up against semaglutide | are peptides legal?
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. DOI 10.1056/NEJMoa2301972.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024. DOI 10.1056/NEJMoa2206038.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID 40353578. DOI 10.1056/NEJMoa2416394.
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMID 38858523.
- US Food and Drug Administration. Tirzepatide approval records: Mounjaro (2022, type 2 diabetes) and Zepbound (2023, chronic weight management).